<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00295542</url>
  </required_header>
  <id_info>
    <org_study_id>PGIDIT03-PXIB-32201PR</org_study_id>
    <secondary_id>SAF2006-6254</secondary_id>
    <secondary_id>INCITE07-PXI-322003ES</secondary_id>
    <nct_id>NCT00295542</nct_id>
  </id_info>
  <brief_title>Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy</brief_title>
  <acronym>MAPEC</acronym>
  <official_title>Prognostic Value of Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy in Relation to Risk (the MAPEC Study).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Vigo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinico Universitario de Santiago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xunta de Galicia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministerio de Educacion y Ciencia, Spain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vigo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The MAPEC study was designed to investigate whether normalizing the circadian blood pressure
      profile towards a more dipper pattern (increasing the diurnal/nocturnal ratio of blood
      pressure) by the use of Chronotherapy (that is, taking into account the time of day of
      administration of antihypertensive medications) reduces cardiovascular risk.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Target organ damage is more closely associated with ambulatory (ABPM) than with clinic blood
      pressure (BP). In particular, the reduction of the normal 10 to 20% sleep-time BP decline
      (non-dipper pattern) is associated with elevated risk of end-organ injury, particularly to
      the heart, brain and kidney. These results suggest that cardiovascular risk could be
      influenced not by BP elevation alone, but also by the magnitude of the circadian BP
      variability. Moreover, at least two independent prospective studies have suggested that
      nighttime BP is a better predictor of risk than daytime BP. Common to all previous trials is
      that prognostic significance of ABPM has relied on a single baseline profile from each
      participant, without accounting for possible changes in the BP pattern, mainly associated to
      antihypertensive therapy and aging during follow-up. The MAPEC study investigates, first, the
      comparative prognostic value of several BP parameters (including, among many others, BP
      variability, the diurnal/nocturnal ratio, diurnal and nocturnal means, slope of morning rise,
      etc) in the prediction of cardiovascular morbidity and mortality; and, second, whether
      potential changes in the circadian BP pattern after Chronotherapy with antihypertensive drugs
      are associated to changes in cardiovascular risk.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">April 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic value of ABPM, impact of changes in ambulatory BP and impact of circadian time of antihypertensive treatment in cardiovascular, cerebrovascular and renal risk assessment.</measure>
    <time_frame>Five years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Influence of circadian time of antihypertensive treatment in BP control and the remodeling of the circadian BP pattern of hypertensive patients.</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence of an altered BP profile as a function of the circadian time of treatment.</measure>
    <time_frame>Five years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3344</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment on awakening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment at bedtime</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Ambulatory blood pressure monitoring</intervention_name>
    <description>Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Chronotherapy, timing of antihypertensive medication</intervention_name>
    <description>Comparison of effects of awakening versus bedtime dosing</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACEI (including spirapril, enalapril, quinapril, lisinopril)</intervention_name>
    <description>Treatment at awakening versus bedtime</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARB (including valsartan, telmisartan, olmesartan)</intervention_name>
    <description>Treatment at awakening versus bedtime</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>beta blockers (including nebivolol, atenolol, carvedilol)</intervention_name>
    <description>Treatment at awakening versus bedtime</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diuretics (torasemide, indapamide, HTCZ) and doxazosin</intervention_name>
    <description>Treatment at awakening versus bedtime</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Combination therapy in essential hypertension</intervention_name>
    <description>Treatment at awakening versus bedtime</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Essential hypertension

        Exclusion Criteria:

          -  AIDS

          -  shift workers

          -  secondary hypertension

          -  intolerant to ABPM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ramon C Hermida, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Vigo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico Universitario</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2006</study_first_submitted>
  <study_first_submitted_qc>February 22, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 23, 2006</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Ramon C. Hermida</name_title>
    <organization>University of Vigo</organization>
  </responsible_party>
  <keyword>ambulatory blood pressure monitoring</keyword>
  <keyword>cardiovascular risk</keyword>
  <keyword>chronotherapy</keyword>
  <keyword>circadian pattern</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Quinapril</mesh_term>
    <mesh_term>Torsemide</mesh_term>
    <mesh_term>Spirapril</mesh_term>
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Nebivolol</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Atenolol</mesh_term>
    <mesh_term>Doxazosin</mesh_term>
    <mesh_term>Indapamide</mesh_term>
    <mesh_term>Diuretics</mesh_term>
    <mesh_term>Adrenergic beta-Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

